2 The new generation of obesity management medications, glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide (Saxenda) and semaglutide (Wegovy), as well as dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide (Zepbound), have demonstrated unprecedented efficacy in weight reduction, averaging 15% to 25% total body weight loss
I was an advisor to Novo Nordisk on the phase two trials, and we were so afraid of the side effects that we advised them to use doses that were too small
While specific guidelines can vary depending on individual circumstances and the type of treatment, some general recommendations can be inferred
Pajares M, Rojo AI, Manda G, Bosca L, Cuadrado A
Watch our interview with the founder of Purity Coffee, Andrew Salisbury, for more information and a community Q&A
This information can help your provider anticipate symptom patterns when adding amoxicillin, but genetics does not predict exact medication response and should not replace clinical assessment